Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
REGULATORY
MHLW Panel to Further Review Positioning of Susmed’s Insomnia App
A Japanese health ministry panel has broadly agreed to endorse a partial change to the existing approval for Susmed’s cognitive behavioral therapy app for insomnia, which has been filed by the Tokyo health tech firm in a bid to obtain…
To read the full story
Related Article
- Susmed Wins Partial Change Approval for Insomnia App, Seeks Coverage
September 8, 2025
- Susmed Seeks Partial Change of Approval for Insomnia App towards Coverage
September 3, 2024
- Susmed Drops Reimbursement Request for Insomnia App
January 30, 2024
- Susmed Bags Japan Approval for Insomnia App
February 20, 2023
- Susmed’s Insomnia App in Line for Approval as Early as January
December 20, 2022
- Susmed’s Insomnia App Up for PAFSC Review on December 19
December 6, 2022
- Shionogi Gets Commercial Rights to Susmed’s Insomnia App
December 28, 2021
REGULATORY
- Kisunla Price Cut Set at 3.93% under Japan’s CEA Scheme
November 6, 2026
- Japan Nudged to Probe Wide Gaps in Biosimilar Uptake
November 6, 2026
- Japan Eyes Multi-Year Investment Support for Wholesalers in FY2027 Budget
November 6, 2026
- Japan Poised to Broker Generic Firms’ Product Consolidation Talks
November 6, 2026
- Japan Issues Guidance on AI Model Use in Drug Manufacturing, Quality Control
November 6, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…